Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

We have investigated striatal dopamine D1 and D2 receptor binding in asymptomatic subjects from Huntington's disease (HD) families using positron emission tomography. Nineteen adult subjects at risk of developing HD were scanned with 11C‐SCH 23390 and 11C‐raclopride to calculate the D1 and D2 receptor binding potential, respectively. Eight of the 19 were shown to have the HD mutation; of these, 4 subjects had significant reductions in striatal dopamine receptor binding. Abnormalities were more common in older subjects and were not correlated with the size of the HD mutation. There was a strong coefficient of correlation between individual levels of striatal D1 and D2 binding in subjects with the mutation. Of 6 other cases with a 50% risk of carrying the HD gene, 1 showed subclinical loss of caudate and putamen D2 binding. Our study suggests that both striatal D1 and D2 dopamine receptors are lost in parallel from both cauudate and putamen in presymptomatic HD and that dopamine receptor binding provides a sensitive means of detecting subclinical striatal dysfunction.

[1]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[3]  A. Harding,et al.  Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium. , 1993, Journal of medical genetics.

[4]  D. Brooks,et al.  Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.

[5]  J. Brandt,et al.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.

[6]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[7]  C. Marsden,et al.  Mutation analysis in patients with possible but apparently sporadic Huntington's disease , 1994, The Lancet.

[8]  M. Gilardi,et al.  Physical performance of the latest generation of commercial positron scanner , 1988 .

[9]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[10]  D. Surmeier,et al.  Dopamine receptor subtypes colocalize in rat striatonigral neurons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Neostriatal dopamine receptors. , 1994 .

[12]  K. Jeffries,et al.  Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease , 1988, Annals of neurology.

[13]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[14]  P. Strange.  Dopamine receptors in the basal ganglia: Relevance to parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[15]  T J Spinks,et al.  Physical performance of a positron tomograph for brain imaging with retractable septa. , 1992, Physics in medicine and biology.

[16]  Stephen J. Fink,et al.  Colocalization of D1 and D2 dopamine receptor mRNAs in striatal neurons , 1993, Brain Research.

[17]  E. Richfield,et al.  Heterogeneous dopamine receptor changes in early and late Huntington's disease , 1991, Neuroscience Letters.

[18]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[19]  David J. Brooks,et al.  A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[22]  D. Surmeier,et al.  Are neostriatal dopamine receptors co-localized? , 1993, Trends in Neurosciences.

[23]  C. Gerfen.  The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.

[24]  L. Iversen,et al.  Huntington's Chorea , 1974 .

[25]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[26]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[27]  E. Spokes,et al.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. , 1980, Brain : a journal of neurology.

[28]  C. Gerfen,et al.  NEOSTRIATAL DOPAMINE RECEPTORS. REPLY , 1994 .

[29]  R A Robb,et al.  A software system for interactive and quantitative visualization of multidimensional biomedical images. , 1991, Australasian physical & engineering sciences in medicine.